O’Melveny Worldwide

Jason Yip has more than a decade of experience advising issuers and sponsors on complex capital markets transactions, especially Hong Kong IPOs and post-listing compliance matters across the technology, consumer, and healthcare sectors. Jason earned both a Bachelor of Laws and a Bachelor of Business Administration (Law) from The University of Hong Kong. This dual background in business and law, combined with his extensive practice, uniquely positions him as a valuable advisor adept at navigating complex commercial and legal issues.

Before joining O’Melveny, Jason worked in the Hong Kong offices of a prominent international law firm and a leading Chinese law firm.

Hong Kong IPOs

Technology and Consumers

  • Guming Holdings Limited (1364.HK) in its US$230 million initial public and listing on the HKEX
  • Midea Group Co., Ltd. (0300.HK) in its US$4 billion A+H listing on the HKEX
  • Mininglamp Technology (2718.HK) in its US$130 million initial public offering and listing on the HKEX
  • Zhuhai Kingsware Artificial Intelligence Co., Ltd. (acting for GTJAI and BOCI) in its proposed listing of on the HKEX
  • XGIMI Tech (acting for CICC) in its proposed A+H listing of on the HKEX
  • Streamax Technology (acting for CICC) in its A+H proposed listing of on the HKEX
  • Robotphoenix Intelligent Technology (acting for ABCI) in its proposed listing of on the HKEX
  • JoulWatt Technology in its proposed A+H listing on the HKEX
  • Hangzhou Tongshifu Cultural and Creative (acting for CMBI) in its proposed listing on the HKEX
  • Quwan Holding Limited (acting for CICC) in its proposed listing of on the HKEX
  • Ximalaya Inc. in its proposed listing of on the HKEX
  • Growatt Technology in its proposed listing on the HKEX
  • OneForce Holdings Limited (1933.HK) in its US$8 million initial public and listing on the HKEX
  • Lifestyle China Group Limited (2136.HK) (acting for BNP Paribas) on its spin-off listing on the HKEX
  • Synergy Group Holdings International Limited (1539.HK) (currently known as Unity Group Holdings International) in its transfer to the Main Board of HKEX Compliance Matters

Healthcare

  • Hanx Biopharmaceuticals (Wuhan) (3378.HK) in its US$75 million initial public offering and listing on the HKEX
  • GeneQuantum Medicine (Suzhou) (acting for CICC and Soochow Securities) in its proposed listing of on the HKEX
  • Nuwacell Biotech (acting for CICC, CMS and GF Securities) in its proposed listing of on the HKEX
  • Guangdong Rong Tai Pharmaceutical (acting for CITIC Securities) in its proposed listing of on the HKEX

Manufacturing and construction

  • Hebei Haiwei Electronic New Material Technology (9609.HK) (acting for CICC) in its US$65 million initial public offering and listing on the HKEX
  • Zhixin Group (2187.HK) in its US$31 million initial public offering and listing on the HKEX
  • Prosper Constructions (6816.HK) in its US$21 million initial public offering and listing on the HKEX
  • Taihe Asphalt Investment Group Holdings Limited in its proposed listing on the HKEX

Real estate

  • Dowell Service Group (2352.HK) in its US$25 million initial public offering and listing on the HKEX

Capital Markets and M&A Transactions

  • Macquarie as overall coordinator in the approximately US$210 million share placement for Time Interconnect Technology Limited (1729.HK)
  • China Travel International Investment Hong Kong (308.HK) in its distribution in specie of its tourism real estate business to its shareholders
  • China Youzan Limited (8083.HK) in a US$269 million major acquisition of Youzan Group
  • Wang Yang Holdings (1735.HK) (acting for Huatai Financial) in a mandatory general offer
  • OneForce Holdings Limited (1933.HK) in a US$11 million major and connected acquisition
  • Doyen International (668.HK) in a very substantial acquisition and very substantial disposal
  • Greens Holdings Ltd (1318.HK) (delisted) (acting for the sponsor) in a proposed reverse takeover and proposed listing on the HKEX
  • Fujian Nuoqi Co., Ltd. (1353.HK) (delisted) on a mandatory unconditional general offer
  • Jiangxi Rimag (2522.HK) on its HK$744 million H shares placings under general mandate
  • Synergy Group Holdings International Limited (1539.HK), on its HK$55 million placing of shares
  • China Saite Group Limited (153.HK) on its offering of US$32 million guaranteed note
  • Synergy Group Holdings International Limited (1539.HK), on its offering of HK$80 million and HK$50 million secured guaranteed notes
  • Doyen International Holdings Limited (668.HK) on its US$25 million bond issuance

Public Companies Compliance Matters

  • Advised various Hong Kong listed companies on regulatory compliance, including Xiaomi Corporation (1810.HK), AIM Vaccine Co., Ltd. (6660.HK), Jiangxi Rimag Group Co., Ltd. (2522.HK), JOINN Laboratories (China) Co., Ltd. (6127.HK), Synergy Group Holdings International Limited (1539.HK), Flying Financial Service Holdings Limited (8030.HK), Doyen International Holdings Limited (668.HK), OneForce Holdings (1933.HK), China Saite Group (153.HK), Prosper Construction Holdings (6816.HK) and China Sanjiang Fine Chemicals (2198.HK)

* Including work performed prior to joining O’Melveny and ongoing proposed listing matters

Languages

  • English
  • Cantonese
  • Mandarin Chinese

Admissions

  • Hong Kong

Education

  • The University of Hong Kong, PCLL; LL.B.; BBA

Professional Activities

Qualification

  • CFA Level I